Blueprint Medicines (NASDAQ: BPMC) reported Q4 EPS of ($1.83), $0.07 worse than the analyst estimate of ($1.76). Revenue for the quarter came in at $1.03 million versus the consensus estimate of $1.68 million.

"Following a year of remarkable clinical progress across our portfolio in 2018, we are focused on executing our '2020 Blueprint' vision to transform Blueprint Medicines into a fully-integrated global precision therapy company," said Jeff Albers, Chief Executive Officer of Blueprint Medicines. "The cornerstone of this effort is our planned NDA submission for avapritinib for patients with PDGFRA Exon 18 mutant GIST and fourth-line GIST in the second quarter. As we work to bring this new therapy to GIST patients who currently have no approved treatment options, we are also partnering with treating physicians, the patient community and testing companies to evolve the GIST treatment paradigm toward precision medicine, with the shared goals of maximizing patient outcomes, enabling efficient clinical trials and delivering value to the healthcare system."

For earnings history and earnings-related data on Blueprint Medicines (BPMC) click here.